Proteins 1 that catalytically inactivate eukaryotic ribosomes have been identified in the
extracts of a wide variety of plants [1–3]. Such ribosome-inactivating proteins can be divided …

Site-specific toxin delivery has been achieved by coupling monoclonal antibodies to the A
chain subunit of phytotoxins such as ricin and abrin. Such hybrid molecules, termed A chain …

Immunotoxins are proteins containing a cell-targeting element linked to a toxin that are
under investigation for next-generation cancer treatment. However, these agents are difficult …

Immunotoxins are a group of protein-based therapeutics, basically comprising two functional
moieties: one is the antibody or antibody Fv fragment that allows the immunotoxin to bind …

Recombinant immunotoxins are chimeric proteins composed of the Fv portion of a
monoclonal antibody (MAb) fused to a portion of a toxin. The Fv replaces the cell-binding …

In this chapter we describe the development of first generation immunotoxins containing
ricin and its A chain. The roles of the ligand, linker and toxin in generating highly specific in …

Immunotoxins (ITs) are attractive anticancer modalities aimed at cancer-specific delivery of
highly potent cytotoxic protein toxins. An IT consists of a targeting domain (an antibody …

Immunotoxins (antibody–toxin fusion proteins) target surface antigens on cancer cells and
kill these cells via toxin-mediated inhibition of protein synthesis. To identify genes controlling …

In the past decade, an increased amount of clinically-oriented research involving
immunotoxins has been published. Immunotoxins are a group of artificially-made cytotoxic …

The use of chemotherapeutic agents to treat cancer has resulted in the cure or amelioration
of some types of human cancer. However, many forms of cancer are either initially …